Description

IVERFRESH 12 MG

Indications

IVERFRESH 12 MG is primarily indicated for the treatment of various parasitic infections. It is commonly used to manage conditions caused by nematodes, such as strongyloidiasis and onchocerciasis, as well as certain ectoparasites like scabies and lice. The medication may also be employed in the treatment of other parasitic infections as deemed appropriate by a healthcare provider.

Mechanism of Action

IVERFRESH 12 MG contains Ivermectin as its active ingredient, which is a broad-spectrum antiparasitic agent. The mechanism of action involves the binding of Ivermectin to specific chloride channels that are mediated by gamma-aminobutyric acid (GABA) in the parasite’s nervous system. This binding leads to an increase in the permeability of the cell membrane to chloride ions, resulting in paralysis and death of the parasites. Additionally, Ivermectin may disrupt the function of other neurotransmitters, further contributing to its antiparasitic effects.

Pharmacological Properties

IVERFRESH 12 MG is characterized by its high lipid solubility, allowing it to penetrate various tissues effectively. The pharmacokinetics of Ivermectin include rapid absorption following oral administration, with peak plasma concentrations typically reached within 4 to 5 hours. The drug is extensively distributed throughout the body, with a volume of distribution ranging from 3 to 5 L/kg. Ivermectin is metabolized primarily in the liver, and its elimination half-life is approximately 12 to 36 hours, depending on the individual’s metabolic rate and other factors. The drug is excreted mainly in feces, with a small percentage eliminated in urine.

Contraindications

IVERFRESH 12 MG should not be administered to individuals with a known hypersensitivity to Ivermectin or any of the excipients in the formulation. Caution is advised when considering the use of IVERFRESH in patients with a history of neurological disorders, as the drug may exacerbate certain conditions. Additionally, it is contraindicated in pregnant and breastfeeding women unless the potential benefits outweigh the risks.

Side Effects

Common side effects associated with IVERFRESH 12 MG may include dizziness, nausea, diarrhea, and fatigue. Some patients may experience more severe reactions, such as allergic reactions, skin rashes, or neurological symptoms like tremors and seizures. It is essential for patients to report any unusual or severe side effects to their healthcare provider promptly. The occurrence of side effects may vary based on individual patient factors, including underlying health conditions and concurrent medications.

Dosage and Administration

The recommended dosage of IVERFRESH 12 MG may vary depending on the specific condition being treated, the patient’s weight, and other individual factors. For adults and children over 15 kg, the typical dose for strongyloidiasis is a single oral dose of 200 mcg/kg. For onchocerciasis, the dosage may be similar, but it is crucial to follow the healthcare provider’s instructions. IVERFRESH should be taken on an empty stomach with water for optimal absorption. It is important not to exceed the recommended dosage to minimize the risk of adverse effects.

Interactions

IVERFRESH 12 MG may interact with other medications, which can either enhance its effects or increase the risk of adverse reactions. Notably, the concomitant use of Ivermectin with other central nervous system depressants may lead to increased sedation or respiratory depression. Additionally, caution should be exercised when using IVERFRESH with medications that are known to induce or inhibit liver enzymes, as these can affect the metabolism of Ivermectin. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before starting treatment with IVERFRESH 12 MG, patients should undergo a thorough medical evaluation. Special precautions should be taken in individuals with liver impairment, as the metabolism of Ivermectin may be affected. Patients with a history of seizures or other neurological disorders should be monitored closely during treatment. It is also important to consider the potential for drug interactions, particularly in patients who are taking multiple medications. Pregnant or breastfeeding women should discuss the risks and benefits of using IVERFRESH with their healthcare provider.

Clinical Studies

Clinical studies have demonstrated the efficacy of IVERFRESH 12 MG in treating various parasitic infections. In randomized controlled trials, Ivermectin has shown significant efficacy in reducing the burden of strongyloidiasis and onchocerciasis, with cure rates exceeding 90% in some populations. Additionally, studies have indicated that the drug is well-tolerated, with a low incidence of severe adverse effects. Ongoing research continues to explore the potential applications of Ivermectin in treating other parasitic infections and its role in public health initiatives, particularly in endemic regions.

Conclusion

IVERFRESH 12 MG is a valuable therapeutic option for the treatment of various parasitic infections. Its mechanism of action, pharmacological properties, and clinical efficacy make it an effective choice in managing conditions such as strongyloidiasis and onchocerciasis. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for ensuring patient safety. Patients are encouraged to consult with their healthcare providers to determine the appropriateness of IVERFRESH in their treatment plan.